

1632/10
P-1
COMBINED AMENDMENT & PETITION FOR EXTENSION OF
TIME UNDER 37 CFR 1.136(a) (Small Entity)

Docket No.
02940139AA

APP 02 2003

In Re Application Of: Schmidt-Ullrich, et al.

Serial No. 09/714,790	Filing Date 11/17/00	Examiner Chen	Group Art Unit 1632
Invention: GENETIC INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR FUNCTION AND CARCINOMA CELL RADIOSENSITIZATION			

APR 08 2003

RECEIVED
TECH CENTER 1600/2900

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

This is a combined amendment and petition under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of 12/17/02 in the above-identified application.

The requested extension is as follows (check time period desired):

One month Two months Three months Four months Five months

from: 03/18/03 Date until: 04/17/03 Date

A verified statement of small entity status as a small entity under 37 CFR 1.27:

is enclosed.
 has already been filed in this application.

The fee for the amendment and extension of time has been calculated as shown below:

CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	35 -	32 =	3	x \$9.00	\$27.00
INDEP. CLAIMS	6 -	3 =	3	x \$42.00	\$126.00
FEE FOR AMENDMENT					\$153.00
FEE FOR EXTENSION OF TIME					\$55.00
TOTAL FEE FOR AMENDMENT AND EXTENSION OF TIME					\$208.00

04/07/2003 WABDEL1R1 00000040 09714790

03 FC:2251

55.00 0P

**COMBINED AMENDMENT & PETITION FOR EXTENSION OF
TIME UNDER 37 CFR 1.136(a) (Small Entity)**

Docket No.
02940139AA



The fee for the amendment and extension of time is to be paid as follows:

A check in the amount of \$208.00 for the amendment and extension of time is enclosed.

Please charge Deposit Account No. in the amount of \$208.00
A duplicate copy of this sheet is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-2041
A duplicate copy of this sheet is enclosed.
 Any additional filing fees required under 37 C.F.R. 1.16.
 Any patent application processing fees under 37 CFR 1.17.

If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. 50-2041 A duplicate copy of this sheet is enclosed.

RECEIVED
APR 08 2003
TECH CENTER 1600/2900

A handwritten signature in black ink, appearing to read "Ruth Tyler-Cross".

Signature

Ruth Tyler-Cross
Reg No. 45,922
Whitham, Curtis & Christofferson, P.C.
11491 Sunset Hills Road, Suite 340
Reston, Virginia 20190
703-787-9400



cc: 30743
PATENT TRADEMARK OFFICE

I certify that this document and fee is being deposited on with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

HAND DELIVERED

Typed or Printed Name of Person Mailing Correspondence



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of Schmidt-Ullrich et al.

Serial No. 09/714,790

Examiner: Chen

Filed: 11/17/2000

Art Unit: 1632

For: **"GENETIC INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR FUNCTION AND CARCINOMA CELL RADIOSENSITIZATION"**

Assistant Commissioner of Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 C.F.R. 1.111

Dear Sir:

In response to the Office Action mailed 12/17/2002, please amend the application as follows:

In the Specification:

Please delete the paragraph beginning on page 8, line 7 and ending on page 8 at line 11 and replace the deleted paragraph with a replacement paragraph, an edited version of which follows and a clean copy of which is attached in Appendix A:

Figure 13. [Transduction efficiency of Ad-EGFR-CD533 at increasing MOI.] Transduction efficiencies of MDA cells with Ad-LacZ at MOI's between 5 and 100. Expression of β -gal was determined by x-gal staining 48 h after transduction. All additional experiments were performed at 50 MOI yielding an overall transduction rate > 80% with < 20% associated cytotoxicity.

Please delete the paragraph beginning on page 50, line 19 and ending on page 51 at line 2 and replace the deleted paragraph with a replacement paragraph, an edited version of which follows and a clean copy of which is attached in Appendix A:

RECEIVED
APR 08 2003
TECH CENTER 1600/2900

126.00 00
27.00 00

04/07/2003 WABDELR1 000000040 09714790

01 FC:2201
02 FC:2202